These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2971386)

  • 1. The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
    Canney PA; Dowsett M; Priestman TJ
    Br J Cancer; 1988 Jul; 58(1):73-6. PubMed ID: 2971386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
    Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
    Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients.
    Etienne MC; Milano G; Frenay M; Renee N; Francois E; Thyss A; Schneider M; Namer M
    J Clin Oncol; 1992 Jul; 10(7):1176-82. PubMed ID: 1535103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
    Husslein P; Egarter C; Eppel W; Salzer H; Spona J
    Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer].
    Kadota K; Wada T; Watatani M; Houjou T; Mori N; Yasutomi M
    Gan To Kagaku Ryoho; 1991 May; 18(6):983-7. PubMed ID: 1827574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.
    Stockdale AD; Rostom AY
    Clin Pharmacokinet; 1989 Mar; 16(3):129-33. PubMed ID: 2524303
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
    Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
    Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer.
    Blossey HC; Bartsch HH; Kanne D; Koebberling J; Nagel GA
    Cancer Chemother Pharmacol; 1982; 8(1):77-81. PubMed ID: 6212156
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.
    Dowsett M; Lal A; Smith IE; Jeffcoate SL
    Br J Cancer; 1987 Mar; 55(3):311-3. PubMed ID: 2952154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of high-dose medroxyprogesterone acetate (MPA) therapy in women with advanced breast cancer.
    Johnson JR; Priestman TJ; Fotherby K; Kelly KA; Priestman SG
    Br J Cancer; 1984 Sep; 50(3):363-6. PubMed ID: 6235831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology.
    Tamassia V; Battaglia A; Ganzina F; Isetta AM; Sacchetti G; Cavalli F; Goldhirsch A; Brunner K; Bernardo G; Robustelli della Cuna G
    Cancer Chemother Pharmacol; 1982; 8(2):151-6. PubMed ID: 6213319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of carcinoma of the breast with high dose oral medroxyprogesterone acetate: does increased bioavailability improve the therapeutic ratio?
    Roberts JT; Bates T; Bozzino JM; Brock JE; Clarke DG; Durrant KR; Evans RG; Tobias JS
    Clin Oncol (R Coll Radiol); 1990 Nov; 2(6):324-7. PubMed ID: 2149061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced breast cancer: response to high dose oral medroxyprogesterone acetate.
    Hedley D; Dalgleish A; Raghavan D; Tattersall MH; Coates A; Fox R
    Aust N Z J Med; 1984 Jun; 14(3):251-4. PubMed ID: 6238589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.
    Halpenny O; Bye A; Cranny A; Feely J; Daly PA
    Med Oncol Tumor Pharmacother; 1990; 7(4):241-7. PubMed ID: 2149401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
    Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
    J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
    Stockdale AD; Chapman D; Mould GP; Rostom AY
    Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medroxyprogesterone acetate: steady-state pharmacokinetics bioequivalence of two oral formulations.
    Pollow K; Kreienberg R; Di Pietro N
    J Cancer Res Clin Oncol; 1989; 115(4):397-9. PubMed ID: 2527239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer.
    Gallagher CJ; Cairnduff F; Smith IE
    Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1895-900. PubMed ID: 2963746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
    Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
    Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.